Skip to Content


Government-Owned Inventions; Availability for Licensing

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


National Institutes of Health, HHS.




The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Start Further Info


Chris Kornak at 240-627-3705 or Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

End Further Info End Preamble Start Supplemental Information


Technology description follows:

Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use

Description of Technology

NIAID has produced recombinant adenovirus type 4 (Ad4), SARS-CoV-2 spike, vectors for administration to humans. These recombinant vaccines permit rapid development of high levels of neutralizing antibodies to SARS-CoV-2 in experimental animals. This vaccine is designed to improve the durability of the immune response by inducing mucosal and systemic immunity. Further, this system should be incredibly simple and efficient when producing vaccine at scale. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications

  • Vaccine composition(s)

Competitive Advantages

  • Stimulates a durable immune response;
  • Induction of mucosal and systemic immunity;
  • Potential for transmission interruption;
  • Intranasal administration minimizes the impact of pre-existing immunity;
  • Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.

Inventor: Mark Connors, M.D. (NIAID)

Publications: Matsuda et al. Journal of Clinical Investigation, 2021. (​10.1172/​JCI140794). Matsuda et al., Science Immunology 2019 (​10.1126/​sciimmunol.aau2710).

Intellectual Property: HHS Reference E-055-2021; Application No. 63/138,221.

Licensing Contact: To license this technology, please contact Chris Kornak at Start Printed Page 9522

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. Interested parties should have the ability to manufacture viruses under cGMP, suitable for Phase 1-2 testing by NIAID. Capabilities for further clinical development, and experience with Phase 3 testing, licensure, and rollout are preferred. For collaboration opportunities, please contact Chris Kornak at

Start Signature

Dated: January 29, 2021.

Surekha Vathyam,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

End Signature End Supplemental Information

[FR Doc. 2021-03044 Filed 2-12-21; 8:45 am]